Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 8/20 | 0.43 |
| ▸ | CACNB4 | O00305 | 3/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.39 |
| ▸ | CACNG3 | O60359 | 3/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | CACNB3 | P54284 | 3/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.39 |
| ▸ | CACNG7 | P62955 | 3/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.39 |
| ▸ | CACNG1 | Q06432 | 3/20 | 0.39 |
| ▸ | CACNB2 | Q08289 | 3/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.39 |
| ▸ | CACNA1E | Q15878 | 3/20 | 0.39 |
| ▸ | CACNA2D4 | Q7Z3S7 | 3/20 | 0.39 |
| ▸ | CACNA2D3 | Q8IZS8 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4693991 | 0.91 | PIK3CD (0.43) | CNR1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL14545592 | 0.88 | CNR1 (0.43) | CNR1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL5516419 | 0.86 | MAPT (0.40) | CNR1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4694942 | 0.84 | CACNB4 (0.53) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL5522413 | 0.78 | PDE10A (0.42) | CNR1 | |
| SCHEMBL5519690 | 0.77 | CNR1 (0.53) | CNR1FAAHCKS1BSKP1SKP2 | |
| SCHEMBL4750473 | 0.77 | CACNB4 (0.52) | CNR1CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4694710 | 0.77 | EP300 (0.42) | CNR1 | |
| SCHEMBL14545603 | 0.75 | MET (0.43) | CNR1 | |
| SCHEMBL14544919 | 0.74 | EP300 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871762-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2006113704-A2 | SUBTITUTED HETEROARYL CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CACNB4 2663/4885CACNA1A 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.